Results 161 to 170 of about 6,247 (199)

Ejection fraction at hospital admission stratifies mortality risk in HFmrEF patients aged ≥ 70 years: a retrospective analysis from a tertiary university institution

Aging Clinical and Experimental Research, 2023
Background During the last few years, increasing focus has been placed on heart failure with mildly reduced ejection fraction (HFmrEF), an intermediate phenotype from preserved to reduced ejection fraction (EF).
Andrea Sonaglioni, Sergio Harari
exaly   +3 more sources

Risk factors of short-term, intermediate-term, and long-term cardiac events in patients hospitalized for HFmrEF

ESC Heart Failure, 2022
Aims Clinical data on the prognostic determinants over varying periods within the same cohort of heart failure with mid‐range or mildly reduced ejection fraction (HFmrEF) remain scarce.
JianPing Zeng, YunLong Zhu, Na Li
exaly   +2 more sources

Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study

European Journal of Internal Medicine, 2019
To determine and compare the demographic characteristics, clinical profile and management of patients with heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) in a Turkish cohort.The APOLLON ...
Bülent Özlek, Oğuzhan Çelik, Kadir Uğur Mert   +2 more
exaly   +3 more sources

Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?

Journal of the American College of Cardiology
No randomized controlled trial has yet demonstrated a statistically significant reduction in mortality in patients with heart failure and mildly reduced ejection (HFmrEF) or heart failure and preserved ejection fraction (HFpEF), in contrast to the ...
Toru Kondo, Kieran F Docherty, John McMurray   +2 more
exaly   +2 more sources

P6197Patients with HFrEF, HFmrEF and HFpEF, are they so different? [PDF]

European Heart Journal, 2017
E Goncalvesova, P Lesny
exaly   +2 more sources

Finerenone in diabetic chronic kidney disease—Real-world insights including patients with HFpEF or HFmrEF

ESC Heart Failure
Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD).
Miroslava Valentova, Michael J Koziolek, Manuel Wallbach   +2 more
exaly   +2 more sources

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis [PDF]

Frontiers in Cardiovascular Medicine
BACKGROUND AND AIMS: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as an integral component of heart failure management, with evidence supporting their benefits across a broad spectrum of ejection fractions.
exaly   +5 more sources

Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFrEF to transplantation [PDF]

European Heart Journal, 2018

exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Prognosis of left ventricular dilatation in HFmrEF

European Heart Journal
Abstract Background Left ventricular (LV) dilatation reflects adverse remodeling in heart failure with mildly reduced ejection fraction (HFmrEF), but its prognostic role remains uncertain. Methods In this analysis, 2 ...
T Schupp, H Steffen, M Reinhardt, A Schmitt, N Abel, F Lau, J Dudda, M Behnes, I Akin   +8 more
openaire   +1 more source

Serum proteomic signatures of atrial fibrillation in HFpEF/HFmrEF

European Journal of Heart Failure
Abstract Background Atrial fibrillation (AF) frequently complicates the clinical course of patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), yet the underlying molecular mechanisms extend far beyond electrical atrial remodelling.
J Vogel, S Jura, S Settelmeier, T Lerchner, F Buehing, L Yahsaly, A Carpinteiro, S Mathew, T Rassaf, L Michel   +9 more
openaire   +1 more source